880813-36-5

Basic information

• Product Name: PhiKan-083 Hydrochloride
• Synonyms: PhiKan-083 Hydrochloride;PhiKan 083;[(9-Ethyl-9H-carbazol-3-yl)methyl](methyl)amine
• CAS NO: 880813-36-5
• Molecular Formula: C16H19ClN2
• Molecular Weight: 274.78846
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 880813-36-5.mol

Chemical Properties

• Boiling Point: 401.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Solubility: <13.74mg/ml in H2O; <27.48mg/ml in DMSO
• PKA: 9.71±0.10(Predicted)
• CAS DataBase Reference: PhiKan-083 Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: PhiKan-083 Hydrochloride(880813-36-5)
• EPA Substance Registry System: PhiKan-083 Hydrochloride(880813-36-5)

Safety Data

• Hazardous Substances Data: 880813-36-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine is used as a p53 stabilizing agent for the treatment of cancer. It is particularly effective in targeting mutated p53 proteins, which are commonly found in various types of cancer. By selectively binding to and stabilizing these mutated p53 proteins, PhiKan-083 can potentially restore their normal function, leading to the inhibition of tumor growth and progression.
Additionally, PhiKan-083 is used as a research tool for studying the role of p53 in cancer development and progression. Its ability to selectively bind to mutated p53 proteins makes it a valuable compound for investigating the molecular mechanisms underlying the regulation of p53 activity and its implications in cancer therapy.
Furthermore, PhiKan-083 can be used in drug discovery and development efforts aimed at identifying novel therapeutic agents that target the p53 pathway. Its unique binding properties and potential therapeutic effects make it a promising candidate for the development of new cancer treatments that can overcome the limitations of existing therapies and improve patient outcomes.

Biological Activity

ki: ≈ 150 mphikan 083 is a critical p53 stabilizing agent by bonding its mutation y220cthe mutation y220c of p53 exists a surface cavity that destabilizes the protein by 4 kcal/mol, at a site that is not functional. a p53 stabilizing agent binding it is able to slow rate of thermal denaturation [1].

in vitro

isothermal titration of phikan083 with t-p53c-y220c exhibited 1:1 stoichiometry and a kd of 125 ± 10 m. phikan083 stabilized t-p53c-y220c in a concentration-dependent manner. in a simple binding model for phikan083 (t-p53c-y220c at 310 k (37°c)), in the absence of ligand, the protein gave a half-life of 3.8 min, while it increased to 15.7 min at saturating concentrations of phikan083. this is a proposed anticancer drug that could be developed for the y220c mutant using p53 stabilizing agent. the site of mutation in the oncogenic y220c mutant phikan083 binds with reasonable affinity is a druggable target. interestingly, the site of mutation does not exist in a region of the protein that is functionally important, it will be an excellent target for drug stabilization therapy. this suggests the crystal structure of the complex will be a fresh start for further rounds of drug design and refinement [1].

references

[1] boeckler fm, joerger ac, jaggi g, rutherford tj, veprintsev db, fersht ar. targeted rescue of a destabilized mutant of p53 by an in silico screened drug. proc natl acad sci u s a. 2008 jul 29; 105(30):10360-5.